WallStreetZenWallStreetZen

NASDAQ: ACAD
Acadia Pharmaceuticals Inc Stock

$15.20-0.34 (-2.19%)
Updated May 24, 2024
ACAD Price
$15.20
Fair Value Price
N/A
Market Cap
$2.51B
52 Week Low
$14.65
52 Week High
$33.99
P/E
-1,520x
P/B
5.41x
P/S
3.74x
PEG
N/A
Dividend Yield
N/A
Revenue
$813.81M
Earnings
-$1.71M
Gross Margin
92.3%
Operating Margin
1.83%
Profit Margin
-0.2%
Debt to Equity
0.84
Operating Cash Flow
$64M
Beta
0.85
Next Earnings
May 29, 2024
Ex-Dividend
N/A
Next Dividend
N/A

ACAD Overview

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Zen Score

Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ACAD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ACAD is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ACAD is good value based on its book value relative to its share price (5.41x), compared to the US Biotechnology industry average (6.08x)
P/B vs Industry Valuation
ACAD is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ACAD due diligence checks available for Premium users.

Be the first to know about important ACAD news, forecast changes, insider trades & much more!

ACAD News

Valuation

ACAD fair value

Fair Value of ACAD stock based on Discounted Cash Flow (DCF)
Price
$15.20
Fair Value
$17.21
Undervalued by
11.70%
ACAD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ACAD price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-1,520x
Industry
15.58x
Market
32.03x

ACAD price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
5.41x
Industry
6.08x
ACAD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ACAD's financial health

Profit margin

Revenue
$205.8M
Net Income
$16.6M
Profit Margin
8%
ACAD's Earnings (EBIT) of $14.91M... subscribe to Premium to read more.
Interest Coverage Financials
ACAD's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$855.1M
Liabilities
$391.1M
Debt to equity
0.84
ACAD's short-term assets ($675.30M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ACAD's short-term assets ($675.30M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ACAD's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ACAD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$29.1M
Investing
-$14.0M
Financing
$1.0M
ACAD's operating cash flow ($63.71M)... subscribe to Premium to read more.
Debt Coverage Financials

ACAD vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
ACAD$2.51B-2.19%-1,520.00x5.41x
TGTX$2.58B-1.59%57.62x16.13x
CLDX$2.43B+1.65%-12.91x2.90x
MLTX$2.61B+2.23%-55.96x4.81x
ARVN$2.41B0.00%-5.82x3.95x

Acadia Pharmaceuticals Stock FAQ

What is Acadia Pharmaceuticals's quote symbol?

(NASDAQ: ACAD) Acadia Pharmaceuticals trades on the NASDAQ under the ticker symbol ACAD. Acadia Pharmaceuticals stock quotes can also be displayed as NASDAQ: ACAD.

If you're new to stock investing, here's how to buy Acadia Pharmaceuticals stock.

What is the 52 week high and low for Acadia Pharmaceuticals (NASDAQ: ACAD)?

(NASDAQ: ACAD) Acadia Pharmaceuticals's 52-week high was $33.99, and its 52-week low was $14.65. It is currently -55.28% from its 52-week high and 3.75% from its 52-week low.

How much is Acadia Pharmaceuticals stock worth today?

(NASDAQ: ACAD) Acadia Pharmaceuticals currently has 165,220,884 outstanding shares. With Acadia Pharmaceuticals stock trading at $15.20 per share, the total value of Acadia Pharmaceuticals stock (market capitalization) is $2.51B.

Acadia Pharmaceuticals stock was originally listed at a price of $6.70 in May 27, 2004. If you had invested in Acadia Pharmaceuticals stock at $6.70, your return over the last 19 years would have been 126.87%, for an annualized return of 4.41% (not including any dividends or dividend reinvestments).

How much is Acadia Pharmaceuticals's stock price per share?

(NASDAQ: ACAD) Acadia Pharmaceuticals stock price per share is $15.20 today (as of May 24, 2024).

What is Acadia Pharmaceuticals's Market Cap?

(NASDAQ: ACAD) Acadia Pharmaceuticals's market cap is $2.51B, as of May 25, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Acadia Pharmaceuticals's market cap is calculated by multiplying ACAD's current stock price of $15.20 by ACAD's total outstanding shares of 165,220,884.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.